Back

Fluid status established by bioimpedance vector analysis (BIVA) at diagnosis of wild-type transthyretin amyloidosis is associated with patient survival

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Improving treatment of transthyretin cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Josephine Mansell

National Amyloidosis Centre, London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Assessing functional capacity in patients with ATTR-CM: the role of CPET and 6MWT
Doctor A. Sheikh (London, GB)
Abstract Slides Video
Presentation thumbnail
Novel self-supervised learning outperforms traditional AI in ECG-based transthyretin cardiac amyloidosis detection for earlier diagnosis
Mr D. Mcauliffe (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Impact of Tafamidis on survival in elderly patients in a real-world setting: insights from the Healthcare European Amyloidosis Registry
Doctor A. Jobbe Duval (Villeurbanne, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Improving treatment of transthyretin cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Distribution and prognostic impact of left and right systolic and diastolic functions in wild-type transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
The value of left atrio-ventricular coupling index (LACI) in transthyretin amyloidosis: insights from a cohort analysis
thumbnail
Congress Session
Novelties in amyloid cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources